Oncopeptides AB (ONPPF)
0.265
-0.13
(-32.72%)
USD |
OTCM |
May 03, 16:00
Oncopeptides Cash from Investing (TTM): -0.2606M for Sept. 30, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | -0.2606M |
| June 30, 2023 | -0.25M |
| March 31, 2023 | -0.25M |
| December 31, 2022 | -0.25M |
| September 30, 2022 | -0.0004M |
| June 30, 2022 | 0.0007M |
| March 31, 2022 | 0.0488M |
| December 31, 2021 | -0.0396M |
| September 30, 2021 | -0.4721M |
| June 30, 2021 | -1.320M |
| March 31, 2021 | -1.889M |
| December 31, 2020 | -2.198M |
| Date | Value |
|---|---|
| September 30, 2020 | -2.020M |
| June 30, 2020 | -1.193M |
| March 31, 2020 | -0.6711M |
| December 31, 2019 | -0.2782M |
| September 30, 2019 | -0.0869M |
| June 30, 2019 | -0.0798M |
| March 31, 2019 | -0.1091M |
| December 31, 2018 | -0.1045M |
| September 30, 2018 | -0.0335M |
| June 30, 2018 | -0.0616M |
| March 31, 2018 | -0.1151M |
| December 31, 2017 | -0.1727M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-2.198M
Minimum
Dec 2020
0.0488M
Maximum
Mar 2022
-0.6227M
Average
-0.2553M
Median
Cash from Investing (TTM) Benchmarks
| Abliva AB | -0.1218M |
| Karolinska Development AB | -3.475M |
| Calliditas Therapeutics AB | -- |
| Olink Holding AB | -22.43M |
| BioInvent International AB | 24.48M |